Related Experiment Video

Updated: May 20, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell

Michaela Döring1, Ulrike Hartmann, Annika Erbacher

  • 1Department of Pediatric Hematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany. Michaela.Doering@med.uni-tuebingen.de

BMC Infectious Diseases
|July 4, 2012
PubMed

Insights

Caspofungin (CAS) and liposomal amphotericin B (L-AmB) showed similar antifungal prophylaxis efficacy in pediatric hematopoietic stem cell transplant (HSCT) patients. CAS was better tolerated with fewer side effects than L-AmB.

Area of Science:

  • Pediatric Hematology
  • Infectious Diseases
  • Transplantation Medicine

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) in children often involves antifungal prophylaxis.
  • Intravenous liposomal amphotericin B (L-AmB) is commonly used, but guidelines for pediatric prophylaxis are lacking.
  • Caspofungin (CAS), an echinocandin, presents a potential alternative with reduced nephrotoxicity.

Purpose of the Study:

  • To retrospectively analyze the safety, feasibility, and efficacy of CAS versus L-AmB for antifungal monoprophylaxis in pediatric HSCT patients.
  • To compare drug-related side effects and electrolyte disturbances between CAS and L-AmB treatments.

Main Methods:

  • Retrospective analysis of 120 pediatric HSCT patients (60 L-AmB, 60 CAS).
  • Antifungal monoprophylaxis initiated on day one post-HSCT.
  • Comparison of safety, feasibility, and efficacy outcomes between the two treatment groups.

Main Results:

  • No proven breakthrough fungal infections occurred in either group during median follow-up of 23-24 days.
  • L-AmB treatment was associated with significant potassium decrease and more drug-related side effects.
  • CAS was well-tolerated and safe, with fewer electrolyte disturbances and side effects compared to L-AmB.

Conclusions:

  • Prophylactic CAS and L-AmB demonstrate comparable efficacy in pediatric allogeneic HSCT patients.
  • CAS appears to be a safer alternative to L-AmB, with better tolerability and fewer side effects.
  • A prospective randomized trial is recommended to establish standardized guidelines for antifungal prophylaxis in this population.
Abstract

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...